Clinical Trial: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07673029) titled 'A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer' on June 17.

Brief Summary: This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Study Start Date: Jan. 10, 2025

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: GQ1005

Administered I.V.

DRUG: T-DM1

Administered I.V.

Recruitment Status: RECRUITING

Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.

Disclaimer: Curated by HT Syndication....